Chimeric Antigen Receptor T Cells and Hematopoietic Cell Transplantation: How Not to Put the CART Before the Horse

Biology of Blood and Marrow Transplantation

Volumn 23, Issue 2, 2017, Pages 235-246

  Kenderian, Saad S ^a,b   Porter, David L ^a,c   Gill, Saar ^a,c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Adoptive immunotherapy; Adoptive T cell therapy; Bone marrow transplantation; CART19; Chimeric antigen receptor T cells; Hematopoietic stem cell transplantation; Immunotherapy

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; CD3 ANTIGEN; CD3 ANTIGEN, ZETA CHAIN; HYBRID PROTEIN; LEUKOCYTE ANTIGEN; LYMPHOCYTE ANTIGEN RECEPTOR; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; SYNTHETIC DNA; T LYMPHOCYTE RECEPTOR;

ACUTE MYELOID LEUKEMIA; ADOPTIVE IMMUNOTHERAPY; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CELL EXPANSION; CELL THERAPY; CHRONIC LYMPHATIC LEUKEMIA; GENE TARGETING; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LEUKEMIA; LYMPHOCYTE DEPLETION; LYMPHOMA; MULTIPLE MYELOMA; MYELOMA; NONHODGKIN LYMPHOMA; REVIEW; T CELL CULTURE; T LYMPHOCYTE; CELL CULTURE; CLINICAL TRIAL (TOPIC); GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; GRAFT VERSUS HOST REACTION; HEMATOLOGIC DISEASE; IMMUNOLOGY; MULTICENTER STUDY (TOPIC); PROCEDURES; PROTEIN DOMAIN; TRANSPLANTATION; TRANSPLANTATION CONDITIONING;

ANTIGENS, CD; CD3 COMPLEX; CELLS, CULTURED; CLINICAL TRIALS AS TOPIC; COSTIMULATORY AND INHIBITORY T-CELL RECEPTORS; GENES, SYNTHETIC; GENETIC VECTORS; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOTHERAPY, ADOPTIVE; MULTICENTER STUDIES AS TOPIC; PROTEIN DOMAINS; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; SINGLE-CHAIN ANTIBODIES; T-LYMPHOCYTES; TRANSDUCTION, GENETIC; TRANSPLANTATION CONDITIONING;

EID: 85006014368     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2016.09.002     Document Type: Review

References (101)

1. 1 Gill, S., June, C.H., Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies. Immunol Rev 263 (2015), 68–89.
2. 2 Gross, G., Waks, T., Eshhar, Z., Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci USA 86 (1989), 10024–10028.
3. 3 Hudecek, M., Sommermeyer, D., Kosasih, P.L., et al. The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity. Cancer Immunol Res 3 (2015), 125–135.
4. 4 Milone, M.C., Fish, J.D., Carpenito, C., et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther 17 (2009), 1453–1464.
5. 5 Pulè, M.A., Straathof, K.C., Dotti, G., et al. A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol Ther 12 (2005), 933–941.
6. 6 Zhao, Z., Condomines, M., van der Stegen, S.J., et al. Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells. Cancer Cell 28 (2015), 415–428.
7. 7 Till, B.G., Jensen, M.C., Wang, J., et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood 112 (2008), 2261–2271.
8. 8 Brentjens, R.J., Latouche, J.B., Santos, E., et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med 9 (2003), 279–286.
9. 9 Hombach, A.A., Heiders, J., Foppe, M., et al. OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4(+) T cells. Oncoimmunology 1 (2012), 458–466.
10. 10 Cheadle, E.J., Rothwell, D.G., Bridgeman, J.S., et al. Ligation of the CD2 co-stimulatory receptor enhances IL-2 production from first-generation chimeric antigen receptor T cells. Gene Ther 19 (2012), 1114–1120.
11. 11 Song, D.G., Ye, Q., Poussin, M., et al. CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo. Blood 119 (2012), 696–706.
12. 12 Guedan, S., Chen, X., Madar, A., et al. ICOS-based chimeric antigen receptors program bipolar Th17/Th1 cells. Blood 124 (2014), 1070–1080.
13. 13 Maude, S.L., Frey, N., Shaw, P.A., et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 371 (2014), 1507–1517.
14. 14 Porter, D.L., Hwang, W.T., Frey, N.V., et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med, 7, 2015, 303ra139.
15. 15 Lee, D.W., Kochenderfer, J.N., Stetler-Stevenson, M., et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385 (2015), 517–528.
16. 16 Davila, M.L., Riviere, I., Wang, X., et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med, 6, 2014, 224ra25.
17. 17 Kochenderfer, J.N., Dudley, M.E., Kassim, S.H., et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol 33 (2015), 540–549.
18. 18 Dong, L., Chang, L-J., Gao, Z., et al. Chimeric antigen receptor 4SCAR19-modified T cells in acute lymphoid leukemia: a phase II multi-center clinical trial in China. Blood, 126, 2015, 3774.
19. 19 Kenderian, S.S., Ruella, M., Gill, S., Kalos, M., Chimeric antigen receptor T-cell therapy to target hematologic malignancies. Cancer Res 74 (2014), 6383–6389.
20. 20 Sadelain, M., Brentjens, R., Rivière, I., The basic principles of chimeric antigen receptor design. Cancer Discov 3 (2013), 388–398.
21. 21 Kochenderfer, J.N., Genetic engineering of T cells in leukemia and lymphoma. Clin Adv Hematol Oncol 12 (2014), 190–192.
22. 22 Maus, M.V., Grupp, S.A., Porter, D.L., June, C.H., Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood 123 (2014), 2625–2635.
23. 23 Kalos, M., June, C.H., Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity 39 (2013), 49–60.
24. 24 Hacein-Bey-Abina, S., von Kalle, C., Schmidt, M., et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 348 (2003), 255–256.
25. 25 Scholler, J., Brady, T.L., Binder-Scholl, G., et al. Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med, 4, 2012, 132ra53.
26. 26 Huang, X., Guo, H., Tammana, S., et al. Gene transfer efficiency and genome-wide integration profiling of Sleeping Beauty, Tol2, and piggyBac transposons in human primary T cells. Mol Ther 18 (2010), 1803–1813.
27. 27 Kebriaei, P., Huls, H., Jena, B., et al. Infusing CD19-directed T cells to augment disease control in patients undergoing autologous hematopoietic stem-cell transplantation for advanced B-lymphoid malignancies. Hum Gene Ther 23 (2012), 444–450.
28. 28 Kebriaei, P., Huls, H., Singh, H., et al. Adoptive therapy using Sleeping Beauty gene transfer system and artificial antigen presenting cells to manufacture T cells expressing CD19-specific chimeric antigen receptor. Blood, 124, 2014, 311.
29. 29 Barrett, D.M., Singh, N., Liu, X., et al. Relation of clinical culture method to T-cell memory status and efficacy in xenograft models of adoptive immunotherapy. Cytotherapy 16 (2014), 619–630.
30. 30 Zhao, Y., Moon, E., Carpenito, C., et al. Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Cancer Res 70 (2010), 9053–9061.
31. 31 Zhao, Y., Zheng, Z., Cohen, C.J., et al. High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation. Mol Ther 13 (2006), 151–159.
32. 32 Kenderian, S.S., Ruella, M., Shestova, O., et al. CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia. Leukemia 29 (2015), 1637–1647.
33. 33 Singh, N., Liu, X., Hulitt, J., et al. Nature of tumor control by permanently and transiently modified GD2 chimeric antigen receptor T cells in xenograft models of neuroblastoma. Cancer Immunol Res 2 (2014), 1059–1070.
34. 34 Beatty, G.L., Haas, A.R., Maus, M.V., et al. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol Res 2 (2014), 112–120.
35. 35 Hinrichs, C.S., Spolski, R., Paulos, C.M., et al. IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy. Blood 111 (2008), 5326–5333.
36. 36 Maus, M.V., Thomas, A.K., Leonard, D.G., et al. Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. Nat Biotechnol 20 (2002), 143–148.
37. 37 Somerville, R.P., Dudley, M.E., Bioreactors get personal. Oncoimmunology 1 (2012), 1435–1437.
38. 38 Terakura, S., Yamamoto, T.N., Gardner, R.A., et al. Generation of CD19-chimeric antigen receptor modified CD8+ T cells derived from virus-specific central memory T cells. Blood 119 (2012), 72–82.
39. 39 Wu, F., Zhang, W., Shao, H., et al. Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy. Cancer Lett 339 (2013), 195–207.
40. 40 Sommermeyer, D., Hudecek, M., Kosasih, P.L., et al. Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo. Leukemia 30 (2016), 492–500.
41. 41 Turtle, C.J., Berger, C., Sommermeyer, D., et al. Anti-CD19 chimeric antigen receptor-modified T cell therapy for B cell non-Hodgkin lymphoma and chronic lymphocytic leukemia: fludarabine and cyclophosphamide lymphodepletion improves in vivo expansion and persistence of CAR-T cells and clinical outcomes. Blood, 126, 2015 184 [abstract].
42. 42 Turtle, C.J., Hanafi, L.A., Berger, C., et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J Clin Invest 126 (2016), 2123–2138.
43. 43 Wang, X., Popplewell, L.L., Wagner, J.R., et al. Phase I studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL. Blood 127 (2016), 2980–2990.
44. 44 Muranski, P., Borman, Z.A., Kerkar, S.P., et al. Th17 cells are long lived and retain a stem cell-like molecular signature. Immunity 35 (2011), 972–985.
45. 45 Kochenderfer, J.N., Wilson, W.H., Janik, J.E., et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 116 (2010), 4099–4102.
46. 46 Porter, D.L., Kalos, M., Zheng, Z., et al. Chimeric antigen receptor therapy for B-cell malignancies. J Cancer 2 (2011), 331–332.
47. 47 Kalos, M., Levine, B.L., Porter, D.L., et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med, 3, 2011, 95ra73.
48. 48 Grupp, S.A., Kalos, M., Barrett, D., et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 368 (2013), 1509–1518.
49. 49 Till, B.G., Jensen, M.C., Wang, J., et al. CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood 119 (2012), 3940–3950.
50. 50 Fry, T.J., Stetler-Stevenson, M., Shah, N.N., et al. Clinical activity and persistence of anti-CD22 chimeric antigen receptor in children and young adults with relapsed/refractory acute lymphoblastic leukemia (ALL). Blood, 126, 2015, 1324.
51. 51 Ali, S.A., Shi, V., Wang, M., et al. Remissions of multiple myeloma during a first-in-humans clinical trial of T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor. Blood, 126, 2015, LBA-1.
52. 52 Ramos, C.A., Ballard, B., Liu, E., et al. Chimeric T cells for therapy of CD30+ Hodgkin and non-Hodgkin lymphomas. Blood, 126, 2015, 185.
53. 53 Wang, Q.S., Wang, Y., Lv, H.Y., et al. Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia. Mol Ther 23 (2015), 184–191.
54. 54 Luo, Y., Chang, L-J., Hu, Y., et al. First-in-man CD123-specific chimeric antigen receptor-modified T cells for the treatment of refractory acute myeloid leukemia. Blood, 126, 2015, 3778.
55. 55 Porter, D.L., Levine, B.L., Kalos, M., et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365 (2011), 725–733.
56. 56 Ramsay, A.G., Johnson, A.J., Lee, A.M., et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest 118 (2008), 2427–2437.
57. 57 Park, J.H., Riviere, I., Wang, X., et al. Implications of minimal residual disease negative complete remission (MRD-CR) and allogeneic stem cell transplant on safety and clinical outcome of CD19-targeted 19-28z CAR modified T cells in adult patients with relapsed, refractory B-cell ALL. Blood, 126, 2015, 682.
58. 58 Grupp, S.A., Maude, S.L., Shaw, P.A., et al. Durable remissions in children with relapsed/refractory ALL treated with T cells engineered with a CD19-targeted chimeric antigen receptor (CTL019). Blood, 126, 2015, 681.
59. 59 Frey, N.V., Shaw, P.A., Hexner, E.O., et al. Optimizing chimeric antigen receptor (CAR) T cell therapy for adult patients with relapsed or refractory (r/r) acute lymphoblastic leukemia (ALL). J Clin Oncol, 34(Suppl), 2016 abstract 7002.
60. 60 Davila, M.L., Kloss, C.C., Gunset, G., Sadelain, M., CD19 CAR-targeted T cells induce long-term remission and B cell aplasia in an immunocompetent mouse model of B cell acute lymphoblastic leukemia. PLoS ONE, 8, 2013, e61338.
61. 61 Lee, D.W., Gardner, R., Porter, D.L., et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124 (2014), 188–195.
62. 62 Brudno, J.N., Somerville, R.P., Shi, V., et al. Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease. J Clin Oncol 34 (2016), 1112–1121.
63. 63 Rheingold, S.R., Chen, L.N., Maude, S.L., et al. Efficient trafficking of chimeric antigen receptor (CAR)-modified T cells to CSF and induction of durable CNS remissions in children with CNS/combined relapsed/refractory ALL. Blood, 126, 2015, 3769.
64. + lymphomas. Blood, 126, 2015, 183.
65. 65 Popplewell, L., Wang, X., Naranjo, A., et al. Phase I studies of cellular immunotherapy using central memory-derived CD19-specific T cells following autologous stem cell transplantation for patients with high-risk intermediate grade B-lineage non-Hodgkin lymphoma. Blood, 126, 2015, 930.
66. 66 Sauter, C.S., Riviere, I., Bernal, Y., et al. Phase I trial of 19-28z chimeric antigen receptor modified T cells (19-28z CAR-T) post-high dose therapy and autologous stem cell transplant (HDT-ASCT) for relapsed and refractory (rel/ref) aggressive B-cell non-Hodgkin lymphoma (B-NHL). J Clin Oncol, 33(Suppl), 2015 abstract 8515.
67. 67 Garfall, A.L., Maus, M.V., Hwang, W-T., et al. Chimeric antigen receptor T cells against CD19 for multiple myeloma. N Engl J Med 373 (2015), 1040–1047.
68. 68 Gill, S., Tasian, S.K., Ruella, M., et al. Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells. Blood 123 (2014), 2343–2354.
69. 69 Mardiros, A., Dos Santos, C., McDonald, T., et al. T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia. Blood 122 (2013), 3138–3148.
70. 70 Pizzitola, I., Anjos-Afonso, F., Rouault-Pierre, K., et al. Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo. Leukemia 28 (2014), 1596–1605.
71. 71 Di Stasi, A., Tey, S.K., Dotti, G., et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med 365 (2011), 1673–1683.
72. 72 Wang, X., Chang, W.C., Wong, C.W., et al. A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood 118 (2011), 1255–1263.
73. 73 Griffioen, M., van Egmond, E.H., Kester, M.G., et al. Retroviral transfer of human CD20 as a suicide gene for adoptive T-cell therapy. Haematologica 94 (2009), 1316–1320.
74. 74 Tasian, S.K., Kenderian, S.S., Shen, F., et al. Efficient termination of CD123-redirected chimeric antigen receptor T cells for acute myeloid leukemia to mitigate toxicity. Blood, 126, 2015, 565.
75. 75 Arora, M., Sun, C.L., Ness, K.K., et al. Physiologic frailty in nonelderly hematopoietic cell transplantation patients: results from the bone marrow transplant survivor study. JAMA Oncol, 2016, 10.1001/jamaoncol.2016.0855 [Epub ahead of print].
76. 76 Porter, D.L., Kalos, M., Frey, N.V., et al. Randomized, phase II dose optimization study of chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed, refractory CLL. Blood, 122, 2013, 873.
77. 77 Frigault, M.J., Lee, J., Basil, M.C., et al. Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells. Cancer Immunol Res 3 (2015), 356–367.
78. 78 Long, A.H., Haso, W.M., Shern, J.F., et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med 21 (2015), 581–590.
79. 79 Kawalekar, O.U., O'Connor, R.S., Fraietta, J.A., et al. Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells. Immunity 44 (2016), 380–390.
80. 80 Fielding, A.K., Richards, S.M., Chopra, R., et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood 109 (2007), 944–950.
81. 81 Brudno, J.N., Somerville, R., Shi, V., et al. Allogeneic T-cells expressing an anti-CD19 chimeric antigen receptor cause remissions of B-cell malignancies after allogeneic hematopoietic stem cell transplantation without causing graft-versus-host disease. Blood, 126, 2015, 99.
82. 82 Lee, D.W., Stetler-Stevenson, M., Yuan, C.M., et al. Safety and response of incorporating CD19 chimeric antigen receptor T cell therapy in typical salvage regimens for children and young adults with acute lymphoblastic leukemia. Blood, 126, 2015, 684.
83. 83 Teachey, D.T., Lacey, S.F., Shaw, P.A., et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov 6 (2016), 664–679.
84. 84 Topp, M.S., Gökbuget, N., Stein, A.S., et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol 16 (2015), 57–66.
85. 85 Sotillo, E., Barrett, D.M., Black, K.L., et al. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov 5 (2015), 1282–1295.
86. 86 Ruella, M., Barrett, D.M., Kenderian, S.S., et al. Combination of anti-CD123 and anti-CD19 chimeric antigen receptor T cells for the treatment and prevention of antigen-loss relapses occurring after CD19-targeted immunotherapies. Blood, 126, 2015, 2523.
87. 87 Qin, H., Haso, W., Nguyen, S.M., Fry, T.J., Preclinical development of bispecific chimeric antigen receptor targeting both CD19 and CD22. Blood, 126, 2015, 4427.
88. 88 Provasi, E., Genovese, P., Lombardo, A., et al. Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer. Nat Med 18 (2012), 807–815.
89. 89 Poirot, L., Philip, B., Schiffer-Mannioui, C., et al. Multiplex genome-edited T-cell manufacturing platform for “off-the-shelf” adoptive T-cell Immunotherapies. Cancer Res 75 (2015), 3853–3864.
90. 90 Cong, L., Ran, F.A., Cox, D., et al. Multiplex genome engineering using CRISPR/Cas systems. Science 339 (2013), 819–823.
91. 91 Qasim, W., Amrolia, P.J., Samarasinghe, S., et al. First clinical application of TALEN engineered universal CAR19 T cells in B-ALL. Blood, 126, 2015, 2046.
92. 92 Ren, J., Liu, X., Fang, C., et al. Multiplex CRIPSR/Cas9 genome editing to generate potent universal CART and PD1-deficient cells against leukemia. Blood, 126, 2015, 4280.
93. 93 Schönfeld, K., Sahm, C., Zhang, C., et al. Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor. Mol Ther 23 (2015), 330–338.
94. 94 Chu, J., Deng, Y., Benson, D.M., et al. CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma. Leukemia 28 (2014), 917–927.
95. 95 Gattinoni, L., Finkelstein, S.E., Klebanoff, C.A., et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med 202 (2005), 907–912.
96. 96 Zah, E., Lin, M.Y., Silva-Benedict, A., et al. T cells expressing CD19/CD20 bispecific chimeric antigen receptors prevent antigen escape by malignant B cells. Cancer Immunol Res 4 (2016), 498–508.
97. 97 Fraietta, J.A., Beckwith, K.A., Patel, P.R., et al. Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood 127 (2016), 1117–1127.
98. 98 Ruella, M., Kenderian, S.S., Shestova, O., et al. The addition of the BTK inhibitor ibrutinib to anti-CD19 chimeric antigen receptor T cells (CART19) improves responses against mantle cell lymphoma. Clin Cancer Res 22 (2016), 2684–2696.
99. 99 Kenderian, S.S., Ruella, M., Shestova, O., et al. Identification of PD1 and TIM3 as checkpoints that limit chimeric antigen receptor T cell efficacy in leukemia. Blood, 126, 2015, 852.
100. 100 Enblad, G., Karlsson, H., Wikstrom, K., et al. Third-generation CD19-CAR T cells for relapsed and refractory lymphoma and leukemia report from the Swedish phase I/IIa trial. Blood, 126, 2015, 1534.
101. 101 Ritchie, D.S., Neeson, P.J., Khot, A., et al. Persistence and efficacy of second-generation CAR T cell against the LeY antigen in acute myeloid leukemia. Mol Ther 21 (2013), 2122–2129.